{"preliminary_commentary":{"by_channel":{"x_thread":28,"podcast":2,"youtube":1,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01368588\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":null,"indication":"unfavorable intermediate or favorable high risk prostate cancer","name":"RTOG 0924","nct_id":"NCT01368588","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rtog-0924-nct01368588. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive androgen deprivation therapy (ADT), consisting of an oral anti androgen plus a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist, for a total duration of 4, 6, or 32 months. Approximately 8-10 weeks after starting the LHRH agent, participants undergo external beam radiation therapy (EBRT) to the prostate and entire seminal vesicles, delivered as 45 Gy in 25 fractions using three-dimensional conformal radiotherapy (3D CRT) or intensity modulated radiotherapy (IMRT). A boost to the prostate and proximal seminal vesicles follows, using either IMRT (34.2 Gy in 19 fractions, with protocol specified dose reduction options when indicated) or brachytherapy delivered as low dose rate (LDR) or high dose rate (HDR) implant per protocol.","label":"Prostate/Seminal Vesicle Radiotherapy + ADT + Prostate Boost (Arm 1)","type":"ACTIVE_COMPARATOR"},{"description":"Participants receive ADT as in Arm 1. Approximately 8-10 weeks after starting the LHRH agent, participants undergo external beam radiation therapy (EBRT) to the whole pelvis-including prostate, seminal vesicles, and pelvic lymph nodes-delivered as 45 Gy in 25 fractions using three-dimensional conformal radiotherapy (3D CRT) or intensity modulated radiotherapy (IMRT). A boost is then administered as specified for Arm 1.","label":"Whole Pelvic Radiotherapy + ADT + Prostate Boost (Arm 2)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)","NRG Oncology"],"completion_date":{"date":"2031-07","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":2590,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"three-dimensional conformal radiotherapy","otherNames":[],"type":"RADIATION"},{"name":"intensity modulated radiotherapy","otherNames":[],"type":"RADIATION"},{"name":"Brachytherapy","otherNames":[],"type":"RADIATION"},{"name":"Anti-androgen","otherNames":[],"type":"DRUG"},{"name":"luteinizing hormone-releasing hormone (LHRH) agonist or antagonist","otherNames":[],"type":"DRUG"}],"last_update":"2026-05-08","lead_sponsor":"Radiation Therapy Oncology Group","official_title":"Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-04-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants Alive (Overall Survival)","timeFrame":"From randomization to death or last follow-up. Median follow-up at time of analysis was 6.8 years. Five- and ten-year estimates are reported."}],"references":[],"start_date":{"date":"2011-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT01368588"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rtog-0924-nct01368588"}